Although targeted treatments for TP53-mutant AML remain limited, hypomethylating agents such as azacitidine and decitabine, along with investigational drugs like APR-246 (eprenetapopt), have been explored in clinical trials, showing promising responses, particularly when used in combination [62,63,64]. This evidence concerns the gene TP53 and acute myeloid leukemia.